NEWS AND PUBLICATIONS
News
10/14/2010
Galenea Awarded $4.5 Million Grant for Advancement of Innovative Synaptic Transmission Screen
12/01/2009
Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
10/06/2009
Galenea Awarded RC1 Challenge Grant to Develop Predictive In Vivo Models of Cognition
10/06/2008
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
05/21/2007
Galenea Corp. Appoints Mark Benjamin as Chief Executive Officer
04/07/2006
Galenea To Focus On Development Of CNS Drugs
02/16/2005
Galenea Corp. Signs Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd.
Publications
Hempel, CM, Sivula, MS, Levenson, JM, Rose, DM, Li, B, Sirianni, AC, Xia, E, Ryan, TA, Gerber, DJ, and Cottrell, JR. (2011) A system for performing high throughput assays of synaptic function. PLoS ONE 6(10): e25999. doi:10.1371/ journal.pone.0025999
Cottrell, JR, Li, B, and Gerber, DJ. (2006) Calcineurin A gamma is expressed in the brain and forms a functional phosphatase. Program No. 588.24. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
Gogos, JA and Gerber, DJ. (2006) Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends in Pharmacological Sciences, 27(4):226-233.
Miyakawa, T et al. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. PNAS, 100(15):8987-92.
Gerber, DJ et al. (2003) Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. PNAS, 100(15):8993-8.
Zeng, H et al. (2001) Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell, 107(5):617-629.